Endocyte, Inc. Initiates Phase 1 Trial of EC0489 for Treatment of Refractory or Metastatic Solid Tumors

May 6, 2009 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Endocyte Inc., has announced the initiation of a Phase 1 clinical trial with EC0489, a folate-targeted anti-cancer drug for the treatment of refractory or metastatic solid tumors.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase I